Literature DB >> 35179650

Disentangling early and late onset of psychosis in women: identifying new targets for treatment.

Alexandre Díaz-Pons1,2, Alexandre González-Rodríguez3, Victor Ortiz-García de la Foz1,4, Mary V Seeman5, Benedicto Crespo-Facorro6, Rosa Ayesa-Arriola7,8,9.   

Abstract

Women present a second peak of incidence of psychosis during the menopausal transition, partially explained by the loss of estrogen protection conferred during the reproductive years. In view of the lack of studies comparing sociodemographic, biological, and clinical variables and neurocognitive performance between women with early onset of psychosis (EOP) and those with late onset of psychosis (LOP), our aim was to characterize both groups in a large sample of 294 first-episode psychosis (FEP) patients and 85 healthy controls (HC). In this cross-sectional study, the participants were interviewed to gather information on sociodemographic variables. We assessed laboratory features of interest and conducted a clinical assessment of psychopathological symptoms and neurocognitive abilities. From the latter, we derived a global cognitive functioning score. Analysis of covariance (ANCOVA) was used to compare EOP and LOP groups, and each group with age-comparable HC. EOP women were more frequently single and unemployed than HC age peers. While cholesterol levels in LOP women were higher than those in EOP women, no statistically significant differences were found in leptin levels. Women with LOP presented with less severe negative symptoms and higher cognitive processing speed scores than women with EOP. Cannabis and alcohol use was greater in EOP than in LOP women. Within the total FEP group, there was a history of significantly more recent traumatic events than in the HC group. Women with EOP and LOP show several sociodemographic and clinical differences, which may be valuable for planning personalized treatment.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Early-onset psychosis; First-episode psychosis; Late-onset psychosis; Neurocognition; Personalized treatment; Women

Mesh:

Year:  2022        PMID: 35179650     DOI: 10.1007/s00737-022-01210-2

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  30 in total

Review 1.  Age of onset of schizophrenia: perspectives from structural neuroimaging studies.

Authors:  Nitin Gogtay; Nora S Vyas; Renee Testa; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

2.  International consensus study of antipsychotic dosing.

Authors:  David M Gardner; Andrea L Murphy; Heather O'Donnell; Franca Centorrino; Ross J Baldessarini
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

3.  Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale.

Authors:  A Flemenbaum; R L Zimmermann
Journal:  Psychol Rep       Date:  1973-06

4.  Premorbid IQ subgroups in first episode non affective psychosis patients: Long-term sex differences in function and neurocognition.

Authors:  Rosa Ayesa-Arriola; Esther Setién-Suero; Karl David Neergaard; Àuria Albacete Belzunces; Fernando Contreras; Neeltje E M van Haren; Benedicto Crespo-Facorro
Journal:  Schizophr Res       Date:  2017-12-21       Impact factor: 4.939

5.  Measurement of premorbid adjustment in chronic schizophrenia.

Authors:  H E Cannon-Spoor; S G Potkin; R J Wyatt
Journal:  Schizophr Bull       Date:  1982       Impact factor: 9.306

6.  Late-onset-psychosis: cognition.

Authors:  Caroline Girard; Martine Simard; Robert Noiseux; Louis Laplante; Michel Dugas; François Rousseau; Nadine Gagnon; François Primeau; Evelyn Keller; Patrick J Bernier
Journal:  Int Psychogeriatr       Date:  2011-03-22       Impact factor: 3.878

7.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

Authors:  N C Andreasen; M Flaum; S Arndt
Journal:  Arch Gen Psychiatry       Date:  1992-08

8.  A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Mariluz Ramirez-Bonilla; Obdulia Martínez-García; Javier Llorca; José Luis Vázquez-Barquero
Journal:  J Clin Psychiatry       Date:  2006-10       Impact factor: 4.384

Review 9.  Estrogens in schizophrenia: progress, current challenges and opportunities.

Authors:  Bodyl A Brand; Janna N de Boer; Iris E C Sommer
Journal:  Curr Opin Psychiatry       Date:  2021-05-01       Impact factor: 4.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.